Z3 Partners

Z3 Partners is a Mumbai-based early-growth VC writing $5M to $25M checks at Series B, Series C, and growth stages into digital enablement, enterprise analytics, and SaaS platforms. The firm’s healthcare interest spans health IT software, digital health, and AI/ML applications with credible enterprise GTM and recurring revenue. Z3 is positioned as a growth-stage technology investor rather than an early-stage explorer, which means the firm wants to see Series B-ready companies with proven product-market fit, established commercial machinery, and the operating maturity to absorb mid-size growth capital responsibly. The geographic focus straddles India and global markets, which suits founders building India-first companies that already have international ambitions or US-market traction with Indian operating leverage. The right founder profile is a CEO running a Series B-ready company with genuine technical depth, a clean ARR profile, defensible enterprise customer concentration logic, and a credible global expansion thesis. The wrong fit is a pre-revenue research-stage company, a consumer brand without B2B economics, or a clinical-services business that needs deep clinical-domain operating support. The right entry path is through warm introductions from Series A leads who frequently syndicate growth rounds, including firms like Lightspeed, Accel, and Sequoia India, and through Mumbai-based operator networks where Z3’s partners are active. When pitching, lead with the ARR trajectory, gross retention, net retention, sales efficiency, and the international expansion playbook; AI capability is welcome but does not substitute for enterprise sales metrics. Avoid leading with a clinical-impact narrative; that can be layered in once the commercial story has landed. Caveats: Z3’s healthcare-specific operating expertise is generalist rather than specialist, so founders should layer clinical-domain advisors and specialist co-investors onto the cap table. The firm’s relatively recent vintage also means the track record of Series C and growth-stage exits is still being built. Use Z3 when you are running a venture-scale technology business with healthcare exposure and need a growth-stage capital partner who can underwrite a global trajectory.